Stock-Based Compensation (Tables)

3 Months Ended

Mar. 30, 2019

Stockholders' Equity Note [Abstract]

Schedule of stock-based compensation expense

The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss (in thousands):

	Fiscal Three Months Ended
	March 30, 2019		March 31, 2018
Cost of revenue	$	3	$	1
Research, development and clinical trials expenses		16		8
Selling, general and administrative expenses		38		18
	$	57	$	27